Randomized, open-label, parallel group, multi-center phase II clinical trial of active cellular immunotherapy with preparation DCVAC/PCa in combination with hormone therapy in patients with metastatic prostate cancer

Trial Profile

Randomized, open-label, parallel group, multi-center phase II clinical trial of active cellular immunotherapy with preparation DCVAC/PCa in combination with hormone therapy in patients with metastatic prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2017

At a glance

  • Drugs Stapuldencel-T (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors SOTIO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 05 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top